Compare
Oral BPC-157 vs injection: what's known in 2026
Oral BPC-157 vs injection: which routes the HHS policy covers, its oral absorption condition, the gastric stability claims, and the missing human absorption data.
By Julian Caraulani · Updated October 30, 2026 · Reviewed by Dr. A. Goher, MBBS
HHS's interim policy covers compounded BPC-157 acetate as an injection under the skin or into muscle, and in oral and topical forms. Oral products carry an extra condition: the pharmacy must document adequate absorption in humans (HHS policy, archived copy). No published human data shows how much oral BPC-157 is absorbed. Injection programs start at $149 a month.
Below: what the policy says route by route, what "stable in gastric juice" does and does not prove, what is known about absorption, where pills and injections stand at prescription programs, and what to ask. Facts were checked on 30 October 2026. Compounded BPC-157 is not FDA-approved, and the policy is interim and can be withdrawn.
Which routes the HHS policy covers
HHS published its enforcement-discretion policy for six peptides in the Federal Register on 30 October 2026. For BPC-157, Appendix B states that "enforcement discretion for BPC-157 acetate is appropriate for subcutaneous, intramuscular, oral, and topical dosage forms" when compounded from an ingredient with a qualifying certificate of analysis (HHS policy, archived copy).
| BPC-157 form | Covered by the interim policy? | Extra condition |
|---|---|---|
| Injection under the skin (subcutaneous) | Yes | Only a 510(k)-cleared syringe may be co-packaged |
| Injection into muscle (intramuscular) | Yes | Same syringe rule |
| Oral (capsule, tablet) | Yes | Pharmacy must document adequate oral bioavailability in humans |
| Topical (cream, gel) | Yes | Quality tests suited to the dosage form |
| Intravenous, nasal or other routes | No | Not listed in Appendix B |
| BPC-157 blended with TB-500 or another peptide | No | Single active ingredient only |
The policy is not approval. The notice says "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed" (Federal Register). For the full conditions, see our HHS peptide policy guide and is BPC-157 legal.
The oral absorption condition
Condition 8 of the policy is about route. It reads: "Achieving adequate oral bioavailability of peptides is inherently difficult and complex" and so "the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans" (HHS policy, archived copy). A footnote on testing adds that injectable forms "should be the standard route of administration (ROA) for peptides due to their low oral bioavailability" (HHS policy, archived copy).
Superpower summarizes the same point on its peptides page: "Six peptides, in specified forms only. Blends aren't covered; oral formulations need evidence of adequate absorption in humans" (Superpower).
The policy does not define "adequate", and it does not say what kind of study counts as documentation. That is the practical gap: the condition asks for human data that, as far as we can find, has not been published.
One more detail. Appendix B describes the ingredient as BPC-157 acetate, and condition 2 requires the substance to have "the identity and limitations in route of administration described in Appendix B" (HHS policy, archived copy). On our reading, other salt forms sometimes marketed for oral use, such as BPC-157 arginate, do not match that identity. Ask the pharmacy which salt it uses.
Price checked Oct 30 · Cancel anytime · Medication included · No email needed
What "stable in gastric juice" means
The case for oral BPC-157 rests on one property. BPC-157 was isolated from a protein in stomach juice, and its developers at the University of Zagreb have long described it as resistant to stomach acid. Their reviews say it is "native to and stable in human gastric juice (for more than 24 h)" (Sikiric 2020, PubMed 32329684) and "native and stable in human gastric juice for more than 24 h" (Sikiric 2024, PubMed 38980576).
Three cautions:
- These statements come from reviews by the same research group, not from an independent study we could read. We did not find the original stability experiment's data in a PubMed abstract.
- Surviving stomach acid is not the same as being absorbed. A peptide can stay intact in the stomach and still pass through the gut without reaching the blood in useful amounts.
- Preclinical studies showing effects after oral use do not establish how much of a human-sized oral product enters the human bloodstream.
A 2026 drug-development review puts both sides in one sentence: "BPC-157 exhibits unusual stability in gastric juice and demonstrates activity via oral, parenteral, and topical routes, yet its human pharmacokinetic profile remains critically undercharacterized" (Mateescu 2026, PubMed 42198317).
What is known about absorption in people
Pharmacokinetics (how a drug is absorbed, spread and cleared) is where the gap is widest.
| Evidence | What it covers | What it tells you about oral use |
|---|---|---|
| He 2022, PubMed 36588717 | Preclinical study of injected BPC-157 in two species | Half-life under 30 minutes after injection; no human or oral human data |
| Lee and Burgess 2025, PubMed 40131143 | Intravenous infusion in 2 adults | Safety pilot of a route the policy does not cover; says nothing about pills |
| NCT02637284 | Phase 1 study of BPC-157 tablets in healthy volunteers, started October 2015 | Registered to measure oral pharmacokinetics; status unknown and no results posted |
| NCT07437547 | Phase 2 placebo-controlled trial of injections under the skin for hamstring strain | Recruiting; tests injection, not pills |
The preclinical study found "the elimination half-life (t1/2) of prototype BPC157 was less than 30 min" after injection (He 2022, PubMed 36588717). Across all routes, a 2025 review counted that "Only three pilot studies have examined BPC-157 in humans" (McGuire 2025, PubMed 40789979). The Zagreb group's reviews also refer to older bowel disease trials under code names, describing it as "proven in clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736)" (Sikiric 2013, PubMed 22950504), but we found no published results from those trials.
Injections are not well studied either. Human evidence for any route is a handful of small, mostly uncontrolled studies; our BPC-157 guide and side effects guide go through them. The difference is that an injection skips the gut, so absorption is less of an open question than effect and safety.
BPC-157 pills vs injections at prescription programs
| Injection | Oral (pill) | |
|---|---|---|
| HHS interim policy | Covered (subcutaneous, intramuscular) | Covered, with the human bioavailability condition |
| Human absorption data | Limited; injection bypasses the gut | None published |
| Superpower, 30 Oct 2026 | Preorder, $149 a month, shipping late November | "Oral BPC" listed as a pill on a waitlist, no price |
Superpower is the only program we track that lists oral BPC-157, and it shows it as a waitlist item (Superpower). Its injection includes a blood panel and clinician follow-up; see our Superpower review and every BPC-157 price.
Capsules or gummies labeled BPC-157 and sold without a prescription are not 503A compounded drugs, so the HHS policy does not cover them, and this site does not list them. See research vs prescription peptides.
What to ask before choosing a form
- For oral products: what human bioavailability data the pharmacy holds to meet the policy's documentation condition, and whether you can see a summary.
- Which salt form the pharmacy uses (the policy describes BPC-157 acetate).
- Which pharmacy compounds the product and whether the ingredient's maker is FDA-registered.
- How to report a side effect, since the policy requires serious adverse events to go to FDA's MedWatch.
Your prescriber sets the form and amount. We do not publish doses.
FAQ
Is oral BPC-157 as effective as injection?
Nobody knows. No published study compares oral and injected BPC-157 in people, and no human data shows how much of an oral product reaches the bloodstream. Developer reviews describe BPC-157 as stable in gastric juice, but stability is not the same as absorption. HHS itself calls injection the standard route for peptides because of low oral bioavailability.
Does the HHS policy allow BPC-157 pills?
Yes, with a condition. The interim policy covers BPC-157 acetate in oral form when a licensed 503A pharmacy compounds it on a prescription, but the pharmacy must keep documentation that the specific formulation achieves adequate oral bioavailability in humans. The policy does not define adequate. Over-the-counter BPC-157 capsules are outside the policy. Checked 30 October 2026.
Is BPC-157 stable in stomach acid?
Reviews by the Zagreb group that developed BPC-157 say it stays native and stable in human gastric juice for more than 24 hours. We could not find the original experiment's data in an abstract, and no independent group has published a confirmation we could read. Even if accurate, surviving the stomach does not show that the peptide is absorbed.
Where can I get oral BPC-157 with a prescription?
Superpower lists oral BPC on a waitlist, with no price, as of 30 October 2026. No other program we track offers it yet. Its injectable BPC-157 is on preorder. Any program must have a clinician evaluate you first, and the pharmacy must meet the policy's oral absorption condition before oral products ship.
Is topical BPC-157 covered?
Topical BPC-157 acetate is one of the four forms the HHS policy covers, alongside subcutaneous injection, intramuscular injection and oral products. The same quality conditions apply, with tests suited to the dosage form. Human data on how much topical BPC-157 passes through skin is as thin as the oral data, so ask the pharmacy what supports its formulation.
Which is safer, oral or injected BPC-157?
Neither has been shown safe in controlled human trials. Injection adds needle risks such as infection at the site, while oral products add the unknown of whether enough is absorbed. A placebo-controlled trial of injections for hamstring strain was recruiting in 2026. Discuss your medical history with the prescribing clinician before choosing either form.
Compare BPC-157 programs on price, labs and oversight on the BPC-157 price page, or see every program on our best peptide programs page.